Výsledky vyhledávání - "Edward Piper"

Pharmacokinetics of tralokinumab in adolescents with asthma: implications for future dosing

Autor: Meena Jain, Piotr Kuna, Dewei She, Iwona Stelmach, Sara Sandbach, Paul Baverel, Balaji Agoram, Edward Piper

Publikováno v: British Journal of Clinical Pharmacology. 80:1337-1349

Aims Tralokinumab, an investigational human immunoglobulin G4 monoclonal antibody, potently and specifically neutralizes interleukin-13, a central mediator of asthma. Tralokinumab has shown improvements in clinical endpoints in adults with uncontroll

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::adc4b9d7c7b0ce12ca4d61499f94ebd3
https://doi.org/10.1111/bcp.12725

Zobrazit plný text záznamu

Efficacy and safety of tralokinumab in patients with severe uncontrolled asthma: a randomised, double-blind, placebo-controlled, phase 2b trial

Autor: Katie Streicher, Stephanie Korn, Koustubh Ranade, Paul M. O'Byrne, Pascal Chanez, Edward Piper, Christopher E. Brightling, Dewei She, Richard Leigh, Richard D. May

Publikováno v: The Lancet Respiratory Medicine. 3:692-701

Summary Background Interleukin 13 is a central mediator of asthma. Tralokinumab is a human interleukin-13 neutralising monoclonal antibody. We aimed to assess the efficacy and safety of two dosing regimens of tralokinumab in patients with severe unco

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::c90e03eb05eae07d592da4d302fc0ecb
https://doi.org/10.1016/s2213-2600(15)00197-6

Zobrazit plný text záznamu

Effect of Anti–IL-13 Treatment on Airway Dimensions in Severe Asthma

Autor: Edward Piper, Gene L. Colice, Meena Jain, Göran Tornling, Martin Braddock, Dewei She, Lars H. Nordenmark, Christopher E. Brightling

Publikováno v: American Journal of Respiratory and Critical Care Medicine. 194:118-120

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4555d84a16d0a29cab8455d88282d8fd
https://doi.org/10.1164/rccm.201511-2224le

Zobrazit plný text záznamu

Effect of tralokinumab on GINA control in severe, uncontrolled asthma

Autor: Gene L. Colice, Peter Wessman, Christopher E. Brightling, Edward Piper

Publikováno v: Airway Pharmacology and Treatment.

Background: In a Phase 2b trial in patients with severe, uncontrolled asthma, the anti–Il-13 monoclonal antibody tralokinumab improved lung function and, in patients with increased baseline periostin and DPP-4, reduced asthma exacerbations [Lancet

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::cf22a427b9edc2458b6b876ed917bcac
https://doi.org/10.1183/1393003.congress-2017.pa4683

Zobrazit plný text záznamu

A randomized, placebo-controlled, single ascending-dose study to assess the safety, tolerability, pharmacokinetics, and immunogenicity of subcutaneous tralokinumab in Japanese healthy volunteers

Autor: Dewei She, Hakop Gevorkyan, Raffaella Faggioni, Edward Piper, Tomoko Yoshioka, Shinya Ueda, Paul Baverel

Publikováno v: Drug metabolism and pharmacokinetics. 33(3)

Tralokinumab is a human monoclonal antibody in clinical development for asthma and atopic dermatitis that specifically neutralizes interleukin-13. This phase I, single-blind, randomized, placebo-controlled, single ascending-dose study assessed the sa

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1f7353ef457e68f3157408870f7c20ee
https://pubmed.ncbi.nlm.nih.gov/29622380

Zobrazit plný text záznamu

Dipeptidyl peptidase-4 (DPP-4) may predict response to tralokinumab in patients with asthma

Autor: Richard M. Martin, Edward Piper, Chrisopher E. Brightling, Philip Brohawn, Gautam Damera, Dewei She, Inna Vainshtein, Meina Liang, Scott Martinez, Koustubh Ranade, Tuyet-Hang Pham, Katie Streicher, Fernanda Pilataxi, Michael Kuziora

Publikováno v: 5.1 Airway Pharmacology and Treatment.

RATIONALE: We sought biomarkers to identify asthma patients (pts) likely to benefit from tralokinumab, an anti–IL-13 IgG4 monoclonal antibody. METHODS: Airway epithelial cells grown in air-liquid interface cultures were stimulated with cytokines wi

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::0a5d5388436bb92441346e6afdb51b73
https://doi.org/10.1183/13993003.congress-2016.oa1796

Zobrazit plný text záznamu

A phase II placebo-controlled study of tralokinumab in moderate-to-severe asthma

Autor: Nestor A. Molfino, Richard D. May, Gregory P. Geba, Chad K. Oh, Christopher E. Brightling, Edward Piper, Dewei She, Robert Niven, Kwai Poon, Chris Kell, Raffaella Faggioni

Publikováno v: European Respiratory Journal. 41:330-338

Pre-clinical data demonstrate a pivotal role for interleukin (IL)-13 in the development and maintenance of asthma. This study assessed the effects of tralokinumab, an investigational human IL-13-neutralising immunoglobulin G4 monoclonal antibody, in

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5ceafd5e84d183f3a1abddf2b49b1a1c
https://doi.org/10.1183/09031936.00223411

Zobrazit plný text záznamu

Lapaquistat Acetate

Autor: Evan A. Stein, Harold E. Bays, Andrea H Spezzi, Jim Pedicano, Edward Piper, Dennis P. O'Brien

Publikováno v: Circulation. 123:1974-1985

Background— Lapaquistat acetate is a squalene synthase inhibitor investigated for the treatment of hypercholesterolemia. Methods and Results— This report summarizes the phase 2 and 3 results from the lapaquistat clinical program, which was halted

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::3dc34f1569c978d68263e47ca5ea5d4b
https://doi.org/10.1161/circulationaha.110.975284

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání